We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01647568
Recruitment Status : Completed
First Posted : July 23, 2012
Last Update Posted : July 23, 2012
Information provided by (Responsible Party):
Linda A Feagins, Dallas VA Medical Center

Brief Summary:

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Condition or disease
Post-polypectomy Bleeding Anti-platelet Therapy Colonoscopy

Study Type : Observational
Actual Enrollment : 715 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : December 2009
Primary Completion Date : March 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
Thienopyridine Users
Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting to the GI lab for elective colonoscopy.

Inclusion Criteria:

  • Patients presenting to the GI lab for elective colonoscopy

Exclusion Criteria:

  • Patients on Coumadin or other anti-coagulants
  • Patients with Inflammatory Bowel Disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647568

United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75216
Sponsors and Collaborators
Dallas VA Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Linda A Feagins, Staff Gastroenterologist, Dallas VA Medical Center
ClinicalTrials.gov Identifier: NCT01647568     History of Changes
Other Study ID Numbers: DVAMC-09-084
First Posted: July 23, 2012    Key Record Dates
Last Update Posted: July 23, 2012
Last Verified: July 2012